<DOC>
	<DOCNO>NCT01511523</DOCNO>
	<brief_summary>A research study compound contain vitamin E , silymarin carnitine , three counter supplement . The investigator hope learn new supplement safely successfully treat fatty liver disease Non Alcoholic Fatty Liver Disease ( NAFLD ) .</brief_summary>
	<brief_title>Study Evaluate Effect RGMA001 Patients With Non Alcoholic Fatty Liver Disease ( NAFLD )</brief_title>
	<detailed_description />
	<mesh_term>Liver Diseases</mesh_term>
	<mesh_term>Fatty Liver</mesh_term>
	<mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
	<criteria>1 . Male female patient age 18 year old . 2 . A clinical histologic radiographic diagnosis NAFLD . 3 . Abnormities normal range hepatic function test consist panel contain ALT , AST , AP , Total bilirubin albumin . 4 . Negative urine pregnancy test ( female childbearing potential ) collect screen follow another negative serum pregnancy test collect within 24 hour prior first dose study drug . 5 . Female patient childbearing potential must adequate birth control . 6 . Willingness give write informed consent willingness participate comply study requirement . 1 . History receive investigational drug ≤ 3 month prior first dose study drug expectation drug use study . Patients enrol study enrol another study either research , diagnostic treatment purpose . 2 . Positive test screen antiHAV IgM Ab , HBsAg , antiHBc IgM Ab , antiHIV Ab . 3 . History evidence medical condition associate chronic liver disease NAFLD ( e.g. , hemochromatosis , viral autoimmune hepatitis , Wilson 's disease , α1antitrypsin deficiency , alcoholic liver disease , and/or toxin exposure ) . 4 . Females pregnant breast feeding . 5 . Platelet count &lt; 90 x 103 / µL ( &lt; 90 x 109 /L ) screening . 6 . Hemoglobin ( Hgb ) concentration &lt; 12 g/dL ( &lt; 120 g/L ) females &lt; 13 g/dL ( &lt; 30 g/L ) males screen . 7 . Any patient baseline increase risk anemia ( e.g. , thalassemia , sickle cell anemia , spherocytosis , history gastrointestinal bleeding ) anemia would medically problematic . 8 . Patients history severe psychiatric disease , include psychosis and/or severe depression , characterize suicide attempt , hospitalization psychiatric disease , period disability result psychiatric disease must psychiatric evaluation screen ensure patient stable patient must agree continued monitor mental health specialist least every 4 week study . 9 . History immunologically mediate disease [ ( e.g. , vasculitis , cryoglobulinemia , inflammatory bowel disease , idiopathic thrombocytopenic purpura , lupus erythematosus , autoimmune hemolytic anemia , scleroderma , severe psoriasis ( define affect &gt; 10 % body , palm one hand equal 1 % , hand foot affect ) , rheumatoid arthritis require intermittent nonsteroidal antiinflammatory medication management , etc . 10 . Patients evidence decompensated liver disease include limited ascites , esophageal varix , hepatic encephalopathy . 11 . History systemic antineoplastic immunomodulatory treatment ( include supraphysiologic dos steroid radiation ) 6 month prior first dose study drug expectation treatment need time study 12 . History evidence decompensated liver disease ChildPugh Grade B high [ Appendix 1 ] , coagulopathy , hyperbilirubinemia , hepatic encephalopathy , hypoalbuminemia , ascites , bleed esophageal varix condition consistent decompensated liver disease . 13 . One follow condition : ( 1 ) poorly control hypertension , OR ( 2 ) screen baseline blood pressure ≥ 160 mmHg systolic OR ( 3 ) screen baseline blood pressure ≥ 100 mmHg diastolic blood pressure . 14 . History bleed disorder anticoagulant use 15 . Type I II diabetes HbA1C &gt; 8.5 % screening . 16 . History evidence chronic pulmonary disease associate functional limitation . 17 . History severe cardiac disease ( e.g . NYHA Functional Class III IV , myocardial infarction within 6 month , ventricular tachyarrhythmias require ongoing treatment , unstable angina significant cardiovascular disease ) . Patients stable coronary artery disease ( e.g. , 6 month bypass surgery , angioplasty without stent placement , etc . ) confirm cardiologist permit . In addition , patient document presumed unstable coronary artery disease , stable unstable cardiovascular disease cerebrovascular disease , second third degree heart block enrol . 18 . History uncontrolled severe seizure disorder . 19 . Evidence active suspect cancer , history malignancy within last 2 year , exception patient basal cell carcinoma excise cure . 20 . Poorly control thyroid dysfunction . 21 . History evidence clinically relevant ophthalmologic disorder due diabetes mellitus hypertension history evidence severe retinopathy ( e.g. , cytomegalovirus , macular degeneration ) . 22 . History major organ transplantation exist functional graft . 23 . History evidence severe illness , condition would make patient , opinion investigator , unsuitable study . 24 . Any herbal supplement contain silymarin , tocopherol , vitamin C , bioflavins , curcumin . For complete list see appendix.3 25 . Consumption nutrient know possess antioxidant activity 26 . Evidence excessive alcohol , drug substance abuse ( exclude marijuana use ) within 1 year first dose .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>Liver</keyword>
	<keyword>Fatty</keyword>
	<keyword>Non Alcoholic</keyword>
	<keyword>Vitamin E</keyword>
	<keyword>Silymarin</keyword>
	<keyword>Carnitine</keyword>
	<keyword>Supplement</keyword>
	<keyword>NAFLD</keyword>
</DOC>